Gyro Tablet 25 mg (Empagliflozin)
Empagliflozin 25mg
Tablet · Prescription medication
Ilyun Pharmaceutical Co., Ltd.
MFDS item code 202102285 · Approved 2021.03.12
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes. It can be administered as monotherapy, and when blood sugar control is inadequate, it can be combined with metformin or other hypoglycemic agents to enhance efficacy. Additionally, it may be added during insulin therapy or when multiple medications do not sufficiently control blood sugar. Special caution is necessary when used in patients with cardiovascular diseases, and usage guidelines based on professional clinical trial information should be observed. This medication improves blood sugar control and manages cardiovascular risk in patients with type 2 diabetes.
The recommended dose of this medicine is 10 mg once daily, whether used as monotherapy or as add-on combination therapy with other antihyperglycemic agents, such as insulin. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3, Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations • Patients with renal impairment No dosage adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistently reduced glomerular filtration rate of < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. Discontinue this medicine if the glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. • Patients with hepatic impairment No dosage adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dosage adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of this medicine is not recommended in patients aged 85 years or older because clinical experience is limited (see Precautions for Use, section 4, General Precautions).
This medication should not be used in certain patients. It should not be administered if there is an allergy to any component of this drug or its active ingredients. Patients with type 1 diabetes or diabetic ketoacidosis should not take this medication. Patients with very impaired kidney function, specifically with a glomerular filtration rate below 30 mL/min/1.73m2 or those on dialysis for end-stage kidney disease should not use this medication. This drug contains lactose, thus it should not be given to patients with lactose intolerance, galactose intolerance, or hereditary lactase deficiency. Patients with mild kidney impairment should use this medication cautiously. Patients with a glomerular filtration rate below 60 mL/min/1.73m2 should not initiate treatment with this drug, and if currently taking, the dosage may need to be reduced or stopped. For patients with end-stage kidney disease or on dialysis, the effectiveness of this medication is not expected, thus it is not used. Caution is advised for patients with mild to moderate heart failure, while it is not recommended for severe heart failure patients. When taken along with medications that can cause hypoglycemia such as insulin or sulfonylureas, the risk of hypoglycemia may increase, and in such cases, dosage adjustment of insulin or these medications may be necessary. While taking this medication, the following adverse reactions may occur. The most common adverse reaction is hypoglycemia, which may occur more frequently when combined with insulin or sulfonylureas. Genital infections (e.g., vulvovaginitis, balanitis), urinary tract infections, and symptoms of increased urination have also been reported. Dehydration, hypotension, and reduced blood pressure due to fluid loss may occur, particularly caution is needed in individuals aged over 75 years. Temporary elevations in serum creatinine or reductions in glomerular filtration rate may appear in blood tests; however, most return to normal after discontinuing treatment. This medication carries a risk of serious side effects such as ketoacidosis and Fournier's gangrene, so symptoms related to these should be reported to healthcare professionals immediately. It is recommended not to use this medication during pregnancy and to avoid its use while breastfeeding. Safety and efficacy in children and adolescents (under 18 years) have not been established, thus it is not used in this age group. No specific toxic symptoms have been reported in cases of overdose, but appropriate treatment is necessary depending on the clinical situation. This medication may interact with other drugs, especially when taken with diuretics, insulin, or sulfonylureas, thus caution is advised, and blood sugar control tests should utilize methods other than the 1,5-AG test. Caution is necessary when driving or operating machinery due to the risk of hypoglycemia. While taking this medication, it should be kept out of reach of children, and transferring it to another container should be avoided.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. The storage temperature should ideally be maintained between 1 to 30 degrees Celsius at room temperature. This helps to sustain the effectiveness and safety of the medication for an extended period.
Light yellow, biconvex, oval film-coated tablet
10 tablets/box [(10 tablets/PTP × 1)], 30 tablets/box [(10 tablets/PTP × 3)], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 25mg
Tablet · Prescription medication
Ilyun Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.